Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Vanguard Information Technology Index Fund ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.67 (market cap $6.04B), while Vanguard Information Technology Index Fund ETF trades at $127.84 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 28.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 5,132,883). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| IOVA | VGT | |
|---|---|---|
Market Cap | $6.04B | $170.20B |
Volume | 14,805,993 | 5,132,883 |
Sector | Health | — |
52-Week High | $14.82 | $129.79 |
52-Week Low | $1.81 | $83.59 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VGT trades at $127.78, down 1.23% today but maintains a bullish technical outlook with strong moving average signals. The ETF, focused on U.S. technology stocks, has delivered exceptional historical returns, averaging over 17% annually. Recent news highlights its low expense ratio and concentration in tech giants like Nvidia, Apple, and Microsoft. A dividend of $0.15 is scheduled for September 2026.
Long-term growth prospects remain favorable given tech sector dominance and AI momentum, but risks include sector concentration, valuation concerns, and potential AI slowdown. Institutional ownership is increasing, with firms like Baird Financial raising stakes significantly. The current price near pivot point resistance at $128 suggests near-term consolidation before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
